Supplement to November December 2014 CME ACTIVITY - Retinal Degeneration - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2014-12-18 14:21:55 Angiology Vascular endothelial growth factor Ranibizumab Bevacizumab Macular degeneration Choroidal neovascularization Genentech Diabetic retinopathy Retinal haemorrhage Medicine Ophthalmology Vision		Supplement to November/December 2014 CME ACTIVITY Add to Reading List Source URL: www.retinatoday.com Download Document from Source Website File Size: 1,19 MB Share Document on Facebook

	CABARET: Carboplatin and bevacizumab in recurrent glioblastoma study (Part 1) The CABARET trial is helping researchers answer an important health question. It is providing evidence for oncologists planning treatment for DocID: 1pDeC - View Document
	LABORATORY SCIENCES Preclinical Evaluation of the Novel Small-Molecule Integrin ␣5␤1 Inhibitor JSM6427 in Monkey and Rabbit Models of Choroidal Neovascularization Grit Zahn, PhD; Dörte Vossmeyer, PhD; Roland Stragi DocID: 1lkvp - View Document
	PRESTATIE- EN TARIEFBESCHIKKING ADD-ON RANIBIZUMAB Nummer Datum inwerkingtreding DocID: 1cIqP - View Document
	FOR IMMEDIATE RELEASE Quinton Oswald Appointed Chief Executive Officer of Neurotech Pharmaceuticals Seasoned Executive Brings Wealth of Experience to Ophthalmic Biotechnology Pioneer, Including Leadership of SARcode Bio DocID: 1a9Xb - View Document
	Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9 www.novartis.ca DocID: 19zgB - View Document